Agency Forms Undergoing Paperwork Reduction Act Review, 39100-39102 [2018-16947]

Download as PDF sradovich on DSK3GMQ082PROD with NOTICES 39100 Federal Register / Vol. 83, No. 153 / Wednesday, August 8, 2018 / Notices comment does not include any sensitive or confidential information. In particular, your comment should not include any sensitive personal information, such as your or anyone else’s Social Security number; date of birth; driver’s license number or other state identification number, or foreign country equivalent; passport number; financial account number; or credit or debit card number. You are also solely responsible for making sure that your comment does not include any sensitive health information, such as medical records or other individually identifiable health information. In addition, your comment should not include any ‘‘trade secret or any commercial or financial information which . . . is privileged or confidential’’—as provided by Section 6(f) of the FTC Act, 15 U.S.C. 46(f), and FTC Rule 4.10(a)(2), 16 CFR 4.10(a)(2)— including in particular competitively sensitive information such as costs, sales statistics, inventories, formulas, patterns, devices, manufacturing processes, or customer names. Comments containing material for which confidential treatment is requested must be filed in paper form, must be clearly labeled ‘‘Confidential,’’ and must comply with FTC Rule 4.9(c). In particular, the written request for confidential treatment that accompanies the comment must include the factual and legal basis for the request, and must identify the specific portions of the comment to be withheld from the public record. See FTC Rule 4.9(c). Your comment will be kept confidential only if the General Counsel grants your request in accordance with the law and the public interest. Once your comment has been posted on the public FTC website—as legally required by FTC Rule 4.9(b)—we cannot redact or remove your comment from the FTC website, unless you submit a confidentiality request that meets the requirements for such treatment under FTC Rule 4.9(c), and the General Counsel grants that request. The FTC Act and other laws that the Commission administers permit the collection of public comments to consider and use in this proceeding as appropriate. The Commission will consider all timely and responsive public comments that it receives on or before October 9, 2018. For information on the Commission’s privacy policy, including routine uses permitted by the VerDate Sep<11>2014 22:37 Aug 07, 2018 Jkt 244001 Privacy Act, see https://www.ftc.gov/ site-information/privacy-policy. Heather Hippsley, Acting Principal Deputy General Counsel. [FR Doc. 2018–16936 Filed 8–7–18; 8:45 am] BILLING CODE 6750–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention [30Day–18–1072] Agency Forms Undergoing Paperwork Reduction Act Review In accordance with the Paperwork Reduction Act of 1995, the Centers for Disease Control and Prevention (CDC) has submitted the information collection request titled Enhanced STD surveillance Network (SSuN) to the Office of Management and Budget (OMB) for review and approval. CDC previously published a ‘‘Proposed Data Collection Submitted for Public Comment and Recommendations’’ notice on March, 15, 2018 to obtain comments from the public and affected agencies. CDC received 37 comments related to the previous notice. This notice serves to allow an additional 30 days for public and affected agency comments. CDC will accept all comments for this proposed information collection project. The Office of Management and Budget is particularly interested in comments that: (a) Evaluate whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information will have practical utility; (b) Evaluate the accuracy of the agencies estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; (c) Enhance the quality, utility, and clarity of the information to be collected; (d) Minimize the burden of the collection of information on those who are to respond, including, through the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology, e.g., permitting electronic submission of responses; and (e) Assess information collection costs. To request additional information on the proposed project or to obtain a copy PO 00000 Frm 00060 Fmt 4703 Sfmt 4703 of the information collection plan and instruments, call (404) 639–7570 or send an email to omb@cdc.gov. Direct written comments and/or suggestions regarding the items contained in this notice to the Attention: CDC Desk Officer, Office of Management and Budget, 725 17th Street NW, Washington, DC 20503 or by fax to (202) 395–5806. Provide written comments within 30 days of notice publication. Proposed Project Enhanced STD surveillance Network (SSuN)—Reinstatement with Change— Division of STD Prevention (DSTDP), National Center for HIV/AIDS, Viral Hepatitis, STD, and TB prevention (NCHHSTP), Centers for Disease Control and Prevention (CDC). Background and Brief Description The Enhanced STD surveillance network project was created to provide enhanced behavioral, demographic, and clinical information on gonorrhea cases reported to state and local health departments, to provide information on patients presenting for care in STD clinical settings, and to provide an infrastructure for identifying emerging sequelae of STDs. Enhanced SSuN continues to be a collaboration between different branches of the CDC Division of STD Prevention and selected state/local public health departments and their associated STD specialty care clinics in the US. Data from enhanced SSuN data is used to (1) provide a dataset of supplemental information on gonorrhea case reports; (2) provide geographic information on case reports of STDs of interest for investigating social determinants of STDs, (3) monitor STD screening, incidence, prevalence, epidemiologic and health care access trends in populations of interest, (4) monitor STD treatment and prevention service practices, and (5) monitor selected adverse health outcomes of STDs, including neuro/ocular syphilis, This project will continue to utilize two distinct surveillance strategies to collect information. The first strategy employs facility-based sentinel surveillance, which will abstract routine standardized data from existing electronic medical records for all patient visits to participating STD clinics during the project period. For the facility-based component of enhanced SSuN, participating sites have developed common protocols stipulating data elements to be collected, including patient demographics, clinical, risk and sexual behaviors. The specified data elements are abstracted by clinic staff from E:\FR\FM\08AUN1.SGM 08AUN1 39101 Federal Register / Vol. 83, No. 153 / Wednesday, August 8, 2018 / Notices existing electronic medical records for all patient visits to participating STD clinics. Some of the participating facilities are satellite clinics of large network providers where clinical data systems are centralized. Hence, there are 10 unique clinic data managers that will be abstracting the facility data. Each of the clinic data managers will spend three hours to extract and transmit data to local/state health departments. Individual patient records are deidentified (all patient-specific identifiers are removed) by clinic staff before being transmitted to health departments, who recode the data into standardized formats before being transmitted to CDC through secure file transport mechanisms. Each enhanced SSuN site will spend 16 hours to recode and transmit the data to CDC every other month. At CDC, data will be aggregated across all participating sites in a common data structure and formatted for analysis. Under this revision, the second strategy, population-based STD surveillance is being expanded to include not only a random sample of reported gonorrhea cases but also include patients diagnosed with early syphilis that report neurologic/ocular manifestations. For the gonorrhea population component, a probability sample of gonorrhea cases (up to 10% of total gonorrhea morbidity for participating jurisdictions) will be contacted by health department staff for a standardized interview either by phone or in-person. Enhanced gonorrhea investigations will also include verification of treatment and an internal health department record review (performed on either all cases or on the sampled cases). The focus of the new population activity focuses on obtaining additional clinical information on early syphilis cases who report neurologic/ocular symptoms. The subset of patients reporting these symptoms are asked to participate in an interview to obtain additional clinical information for a more complete assessment of neurologic/ocular involvement as well as obtain additional clinical information from the diagnosing or reporting provider. Lastly, early syphilis cases reporting neurologic and/ or ocular symptoms are recontacted at approximately three months following prescribed treatment to ascertain whether initial symptoms have resolved. The population data will be directly entered into existing STD surveillance information systems at each health department. Data will be locally extracted, de-identified and recoded into standardized formats prior to being transmitted to CDC through secure file transport mechanisms on bimonthly basis. Patient participation in the interview is voluntary and refusal to participate has no impact on other STD services the health department provides to persons diagnosed with gonorrhea. This project will not collect name, social security number, or date of birth. A Patient ID, a unique patient identifier assigned by the clinic or health department depending on the component, is requested and will be provided to CDC for purposes of enhanced surveillance. Patient IDs are not linkable across enhanced SSuN components. Sensitive information such as sex of sex partners, HIV status, sex work exposure, and injection drug use are collected. All personally identifiable information (PII) is retained by the STD clinics and/or health departments and is not recorded with data sent to CDC. The electronic enhanced SSuN database is stored on the CDC mainframe computer and only approved Division of STD Prevention (DSTDP) staff have access rights to the data. As part of the revision, we will continue to systematically identify the risks and potential effects of collecting, maintaining, and disseminating PII and to examine and evaluate alternative processes for handling that information to mitigate potential privacy risks and risks to confidentiality. Both components of enhanced SSuN are designed to (1) Integrate traditional surveillance methods with innovative data management technologies to produce high-quality, timely surveillance and epidemiologic data, (2) provide valuable information to direct public health STD prevention and control efforts, (3) enhance understanding of the community burden of disease, (4) identify syndemic patterns and population at greatest risk, and, (5) monitor long-term health consequences of STDs. The enhanced SSuN surveillance platform allows CDC to establish and maintain common standards for data collection, transmission, and analysis, and to build and maintain STD surveillance expertise in 10 state/local health departments. Such common systems, established mechanisms of communication, and in-place expertise are all critical components for timely, flexible, and high quality surveillance. The total estimated annual burden is 3,479 hours. There are no costs to respondents other than their time. ESTIMATED ANNUALIZED BURDEN HOURS Number of respondents Number of responses per respondent Average burden per response (in hours) Form name Data manager at Sentinel STD clinics ........... General Public—Adults (persons diagnosed and reported with gonorrhea or early syphilis. Diagnosing Provider ........................................ General Public—Adults (persons with early syphilis who were reported with neurologic/ ocular manifestations. Data Managers: 10 local/state health department. sradovich on DSK3GMQ082PROD with NOTICES Type of respondents Record Abstraction ......................................... Interview ......................................................... 10 5492 6 1 3 10/60 Data for early syphilis cases .......................... 3 month follow-up telephone Interview .......... 406 203 1 1 10/60 5/60 Data cleaning/validation/reformatting ............. 10 12 19 VerDate Sep<11>2014 22:37 Aug 07, 2018 Jkt 244001 PO 00000 Frm 00061 Fmt 4703 Sfmt 4703 E:\FR\FM\08AUN1.SGM 08AUN1 39102 Federal Register / Vol. 83, No. 153 / Wednesday, August 8, 2018 / Notices Jeffrey M. Zirger, Acting Chief, Information Collection Review Office, Office of Scientific Integrity, Office of the Associate Director for Science, Office of the Director, Centers for Disease Control and Prevention. [FR Doc. 2018–16947 Filed 8–7–18; 8:45 am] BILLING CODE 4163–18–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. FDA–2018–N–2485] Fougera Pharmaceuticals, Inc., et al.; Withdrawal of Approval of 27 Abbreviated New Drug Applications AGENCY: Food and Drug Administration, HHS. ACTION: Notice. The holders of the applications listed in the table have informed FDA that these drug products are no longer marketed and have requested that FDA withdraw approval of the applications under the process described in § 314.150(c) (21 CFR 314.150(c)). The applicants have also, by their requests, waived their opportunity for a hearing. Withdrawal of approval of an application or abbreviated application under § 314.150(c) is without prejudice to refiling. SUPPLEMENTARY INFORMATION: The Food and Drug Administration (FDA or Agency) is withdrawing approval of 27 abbreviated new drug applications (ANDAs) from multiple applicants. The holders of the applications notified the Agency in writing that the drug products were no longer marketed and requested that the approval of the applications be withdrawn. DATES: Approval is withdrawn as of September 7, 2018. FOR FURTHER INFORMATION CONTACT: Trang Tran, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 75, Rm. 1671, Silver Spring, MD 20993–0002, 240–402–7945, Trang.Tran@fda.hhs.gov. SUMMARY: Application No. Drug Applicant ANDA 061467 ......... Pyocidin-Otic (hydrocortisone and polymyxin B sulfate) Otic Solution, 5 milligrams (mg)/10,000 units per milliliter (mL). ANDA 061653 ......... Tetrex (tetracycline phosphate complex) Capsules, Equivalent to (EQ) 100 mg Hydrochloride (HCl), EQ 250 mg HCl and EQ 500 mg HCl. Bristacycline (tetracycline HCl) Capsules, 250 mg and 500 mg ........................... Penicillin V Potassium Tablets .............................................................................. Ampicillin Capsules, 250 mg and 500 mg ............................................................. Azotrex (phenazopyridine HCl, sulfamethizole and tetracycline phosphate complex) Capsules, 50 mg/250 mg/125 mg. Hetacillin Potassium ............................................................................................... Bristamycin (erythromycin stearate) Tablets, EQ 250 mg base ........................... Bristacycline (tetracycline HCl) Capsules, 250 mg and 500 mg ........................... Tetrex (tetracycline phosphate complex) Capsules, EQ 250 mg HCl and EQ 500 mg HCl. Azotrex (phenazopyridine HCl, sulfamethizole, and tetracycline) Capsules, 50 mg/250 mg/125 mg. Tetrex-S (tetracycline) Syrup, 125 mg/5 mL ......................................................... Cephradine Powder for Injection ........................................................................... Cephradine Tablets ................................................................................................ Amphotericin B for Use in Parenteral Products .................................................... Mycolog (nystatin, neomycin sulfate, gramicidin, and triamcinolone acetonide) Ointment. Foamcoat (aluminum hydroxide; magnesium trisilicate) Chewable Tablets, 80 mg/20 mg (OTC). Nuprin (ibuprofen) Tablets, 200 mg ....................................................................... Nuprin (ibuprofen) Tablets, 200 mg ....................................................................... Phrenilin with Caffeine and Codeine (acetaminophen, butalbital, caffeine, and codeine phosphate) Capsules, 325 mg/50 mg/40 mg/30 mg. Fougera Pharmaceuticals, Inc., 60 Baylis Rd., P.O. Box 2006, Melville, NY 11747. Bristol-Myers Squibb Co., P.O. Box 4000, Princeton, NJ 08543. Do. Do. Do. Do. ANDA ANDA ANDA ANDA 061658 061711 061721 061726 ......... ......... ......... ......... ANDA ANDA ANDA ANDA 061790 061887 061888 061889 ......... ......... ......... ......... ANDA 061890 ......... ANDA ANDA ANDA ANDA ANDA 061891 061975 062168 062259 062543 ......... ......... ......... ......... ......... ANDA 071793 ......... ANDA 072035 ......... ANDA 072036 ......... ANDA 074911 ......... ANDA 074944 ......... Atracurium Besylate Injection, 10 mg/mL .............................................................. ANDA 075206 ......... ANDA 077930 ......... Cytosar-U (cytarabine) for Injection USP, 100 mg/vial, 500 mg/vial, 1 gram (g)/ vial, and 2 g/vial. Rosiglitazone Maleate and Metformin HCl Tablets, EQ 1 mg base/500 mg, EQ 2 mg base/500 mg, EQ 4 mg base/500 mg, EQ 2 mg base/1 g, and EQ 4 mg base/1 g. Meloxicam Tablets, 7.5 mg and 15 mg ................................................................. ANDA 080658 ......... Procaine HCl Injection, 1% and 2% ...................................................................... ANDA 083128 ......... ANDA 090181 ......... Hydrocortisone Acetate Injectable Suspension, 25 mg/mL ................................... Ifosfamide for Injection, 1 g/20 mL and 3 g/60 mL ............................................... sradovich on DSK3GMQ082PROD with NOTICES ANDA 077337 ......... VerDate Sep<11>2014 22:37 Aug 07, 2018 Jkt 244001 PO 00000 Frm 00062 Fmt 4703 Sfmt 4703 E:\FR\FM\08AUN1.SGM Do. Do. Do. Do. Do. Do. Do. Do. Do. Do. Guardian Drug Co., 2 Charles Court, Dayton, NJ 08810. Bristol-Myers Squibb Co. Do. Valeant Pharmaceuticals North America, LLC, 400 Somerset Corporate Blvd., Bridgewater, NJ 08807. Watson Laboratories, Inc., Subsidiary of Teva Pharmaceuticals USA, Inc., 425 Privet Rd., Horsham, PA 19044. Teva Pharmaceuticals USA, Inc., 425 Privet Rd., Horsham, PA 19044. Do. Impax Laboratories, Inc., 30831 Huntwood Ave., Hayward, CA 94544. Watson Laboratories, Inc., Subsidiary of Teva Pharmaceuticals USA, Inc. Do. Fresenius Kabi USA, LLC, Three Corporate Dr., Lake Zurich, IL 60047. 08AUN1

Agencies

[Federal Register Volume 83, Number 153 (Wednesday, August 8, 2018)]
[Notices]
[Pages 39100-39102]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-16947]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

[30Day-18-1072]


Agency Forms Undergoing Paperwork Reduction Act Review

    In accordance with the Paperwork Reduction Act of 1995, the Centers 
for Disease Control and Prevention (CDC) has submitted the information 
collection request titled Enhanced STD surveillance Network (SSuN) to 
the Office of Management and Budget (OMB) for review and approval. CDC 
previously published a ``Proposed Data Collection Submitted for Public 
Comment and Recommendations'' notice on March, 15, 2018 to obtain 
comments from the public and affected agencies. CDC received 37 
comments related to the previous notice. This notice serves to allow an 
additional 30 days for public and affected agency comments.
    CDC will accept all comments for this proposed information 
collection project. The Office of Management and Budget is particularly 
interested in comments that:
    (a) Evaluate whether the proposed collection of information is 
necessary for the proper performance of the functions of the agency, 
including whether the information will have practical utility;
    (b) Evaluate the accuracy of the agencies estimate of the burden of 
the proposed collection of information, including the validity of the 
methodology and assumptions used;
    (c) Enhance the quality, utility, and clarity of the information to 
be collected;
    (d) Minimize the burden of the collection of information on those 
who are to respond, including, through the use of appropriate 
automated, electronic, mechanical, or other technological collection 
techniques or other forms of information technology, e.g., permitting 
electronic submission of responses; and
    (e) Assess information collection costs.
    To request additional information on the proposed project or to 
obtain a copy of the information collection plan and instruments, call 
(404) 639-7570 or send an email to [email protected]. Direct written comments 
and/or suggestions regarding the items contained in this notice to the 
Attention: CDC Desk Officer, Office of Management and Budget, 725 17th 
Street NW, Washington, DC 20503 or by fax to (202) 395-5806. Provide 
written comments within 30 days of notice publication.

Proposed Project

    Enhanced STD surveillance Network (SSuN)--Reinstatement with 
Change--Division of STD Prevention (DSTDP), National Center for HIV/
AIDS, Viral Hepatitis, STD, and TB prevention (NCHHSTP), Centers for 
Disease Control and Prevention (CDC).

Background and Brief Description

    The Enhanced STD surveillance network project was created to 
provide enhanced behavioral, demographic, and clinical information on 
gonorrhea cases reported to state and local health departments, to 
provide information on patients presenting for care in STD clinical 
settings, and to provide an infrastructure for identifying emerging 
sequelae of STDs.
    Enhanced SSuN continues to be a collaboration between different 
branches of the CDC Division of STD Prevention and selected state/local 
public health departments and their associated STD specialty care 
clinics in the US. Data from enhanced SSuN data is used to (1) provide 
a dataset of supplemental information on gonorrhea case reports; (2) 
provide geographic information on case reports of STDs of interest for 
investigating social determinants of STDs, (3) monitor STD screening, 
incidence, prevalence, epidemiologic and health care access trends in 
populations of interest, (4) monitor STD treatment and prevention 
service practices, and (5) monitor selected adverse health outcomes of 
STDs, including neuro/ocular syphilis,
    This project will continue to utilize two distinct surveillance 
strategies to collect information. The first strategy employs facility-
based sentinel surveillance, which will abstract routine standardized 
data from existing electronic medical records for all patient visits to 
participating STD clinics during the project period. For the facility-
based component of enhanced SSuN, participating sites have developed 
common protocols stipulating data elements to be collected, including 
patient demographics, clinical, risk and sexual behaviors. The 
specified data elements are abstracted by clinic staff from

[[Page 39101]]

existing electronic medical records for all patient visits to 
participating STD clinics. Some of the participating facilities are 
satellite clinics of large network providers where clinical data 
systems are centralized. Hence, there are 10 unique clinic data 
managers that will be abstracting the facility data. Each of the clinic 
data managers will spend three hours to extract and transmit data to 
local/state health departments. Individual patient records are de-
identified (all patient-specific identifiers are removed) by clinic 
staff before being transmitted to health departments, who recode the 
data into standardized formats before being transmitted to CDC through 
secure file transport mechanisms. Each enhanced SSuN site will spend 16 
hours to recode and transmit the data to CDC every other month. At CDC, 
data will be aggregated across all participating sites in a common data 
structure and formatted for analysis.
    Under this revision, the second strategy, population-based STD 
surveillance is being expanded to include not only a random sample of 
reported gonorrhea cases but also include patients diagnosed with early 
syphilis that report neurologic/ocular manifestations. For the 
gonorrhea population component, a probability sample of gonorrhea cases 
(up to 10% of total gonorrhea morbidity for participating 
jurisdictions) will be contacted by health department staff for a 
standardized interview either by phone or in-person. Enhanced gonorrhea 
investigations will also include verification of treatment and an 
internal health department record review (performed on either all cases 
or on the sampled cases). The focus of the new population activity 
focuses on obtaining additional clinical information on early syphilis 
cases who report neurologic/ocular symptoms. The subset of patients 
reporting these symptoms are asked to participate in an interview to 
obtain additional clinical information for a more complete assessment 
of neurologic/ocular involvement as well as obtain additional clinical 
information from the diagnosing or reporting provider. Lastly, early 
syphilis cases reporting neurologic and/or ocular symptoms are 
recontacted at approximately three months following prescribed 
treatment to ascertain whether initial symptoms have resolved.
    The population data will be directly entered into existing STD 
surveillance information systems at each health department. Data will 
be locally extracted, de-identified and recoded into standardized 
formats prior to being transmitted to CDC through secure file transport 
mechanisms on bimonthly basis. Patient participation in the interview 
is voluntary and refusal to participate has no impact on other STD 
services the health department provides to persons diagnosed with 
gonorrhea.
    This project will not collect name, social security number, or date 
of birth. A Patient ID, a unique patient identifier assigned by the 
clinic or health department depending on the component, is requested 
and will be provided to CDC for purposes of enhanced surveillance. 
Patient IDs are not linkable across enhanced SSuN components. Sensitive 
information such as sex of sex partners, HIV status, sex work exposure, 
and injection drug use are collected. All personally identifiable 
information (PII) is retained by the STD clinics and/or health 
departments and is not recorded with data sent to CDC. The electronic 
enhanced SSuN database is stored on the CDC mainframe computer and only 
approved Division of STD Prevention (DSTDP) staff have access rights to 
the data. As part of the revision, we will continue to systematically 
identify the risks and potential effects of collecting, maintaining, 
and disseminating PII and to examine and evaluate alternative processes 
for handling that information to mitigate potential privacy risks and 
risks to confidentiality.
    Both components of enhanced SSuN are designed to (1) Integrate 
traditional surveillance methods with innovative data management 
technologies to produce high-quality, timely surveillance and 
epidemiologic data, (2) provide valuable information to direct public 
health STD prevention and control efforts, (3) enhance understanding of 
the community burden of disease, (4) identify syndemic patterns and 
population at greatest risk, and, (5) monitor long-term health 
consequences of STDs. The enhanced SSuN surveillance platform allows 
CDC to establish and maintain common standards for data collection, 
transmission, and analysis, and to build and maintain STD surveillance 
expertise in 10 state/local health departments. Such common systems, 
established mechanisms of communication, and in-place expertise are all 
critical components for timely, flexible, and high quality 
surveillance. The total estimated annual burden is 3,479 hours. There 
are no costs to respondents other than their time.

                                        Estimated Annualized Burden Hours
----------------------------------------------------------------------------------------------------------------
                                                                                     Number of    Average burden
          Type of respondents                   Form name            Number of     responses per   per response
                                                                    respondents     respondent      (in hours)
----------------------------------------------------------------------------------------------------------------
Data manager at Sentinel STD clinics..  Record Abstraction......              10               6               3
General Public--Adults (persons         Interview...............            5492               1           10/60
 diagnosed and reported with gonorrhea
 or early syphilis.
Diagnosing Provider...................  Data for early syphilis              406               1           10/60
                                         cases.
General Public--Adults (persons with    3 month follow-up                    203               1            5/60
 early syphilis who were reported with   telephone Interview.
 neurologic/ocular manifestations.
Data Managers: 10 local/state health    Data cleaning/validation/             10              12              19
 department.                             reformatting.
----------------------------------------------------------------------------------------------------------------



[[Page 39102]]

Jeffrey M. Zirger,
Acting Chief, Information Collection Review Office, Office of 
Scientific Integrity, Office of the Associate Director for Science, 
Office of the Director, Centers for Disease Control and Prevention.
[FR Doc. 2018-16947 Filed 8-7-18; 8:45 am]
 BILLING CODE 4163-18-P


This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.